Filing Details
- Accession Number:
- 0001209191-15-002257
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-01-06 16:48:43
- Reporting Period:
- 2015-01-02
- Filing Date:
- 2015-01-06
- Accepted Time:
- 2015-01-06 16:48:43
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1190290 | Elaine Ullian | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-01-02 | 5,000 | $34.32 | 10,265 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-01-02 | 100 | $118.91 | 10,165 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-01-02 | 1,700 | $122.15 | 8,465 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-01-02 | 3,100 | $122.96 | 5,365 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-01-02 | 100 | $123.57 | 5,265 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2015-01-02 | 5,000 | $0.00 | 5,000 | $34.32 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2016-05-31 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $122.15 (range $121.53 to $122.48).
- Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $122.96 (range $122.54 to $123.41).
- Fully vested.